Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, early

3679 - Gestational breast cancer: distinctive molecular and clinico-epidemiological features. GEICAM/2012-03 study


08 Oct 2016


Breast cancer, early


Juan de la Haba


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


J. de la Haba1, A. Ruiz2, M. Pollan3, A. Prat4, F. Rojo5, M. Martin6, E. Alba Conejo7, J.A. Perez-Fidalgo8, J. Gavilá9, C. Morales10, B. Navarro11, A. Hernández-Blanquisett2, I. Porras10, A. Rodriguez-Lescure12, B. Jiménez-Rodríguez13, N. Martín14, L. Pérez-Ramos15, R. Caballero16, E. Carrasco17, A. Lluch-Hernandez18

Author affiliations

  • 1 Medical Oncology, Hospital Universitario Reina Sofía, 14004 - Cordoba/ES
  • 2 Medical Oncology, Fundación Instituto Valenciano de Oncología, 460009 - Valencia/ES
  • 3 Cancer Epidemiology, Instituto de Salud Carlos III (ISCIII), Madrid/ES
  • 4 Translational Genomics Group, Vall d’Hebron Institute of Oncology (VHIO),, 08035 - Barcelona/ES
  • 5 Pathology Department, University Hospital "Fundacion Jimenez Diaz", Madrid/ES
  • 6 Medical Oncology, 6Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Madrid/ES
  • 7 Medical Oncology, Hospital Universitario Regional y Virgen de la Victoria. IBIMA, Malaga/ES
  • 8 Oncology, Hospital Clinico Universitario de Valencia. Instituto de Investigación Sanitaria (INCLIVA), Valencia/ES
  • 9 Medical Oncology, Fundación Instituto Valenciano de Oncología, 46008 - Valencia/ES
  • 10 Medical Oncology, University Hospital Reina Sofia(Andalussian Health Service), IMIBIC, 14004 - Cordoba/ES
  • 11 Medical Oncology, 8Hospital Clinico Universitario de Valencia. Instituto de Investigación Sanitaria (INCLIVA), Valencia/ES
  • 12 Medical Oncology, Hospital General Universitario de Elche, Elche/ES
  • 13 Hospital Universitario Regional Y Virgen De La Victoria, Instituto de Investigacion Biomedica de Malaga (IBIMA), 29010 - Malaga/ES
  • 14 Translational Research, GEICAM Spanish Breast Cancer Group, Madrid/ES
  • 15 Statistics, GEICAM Spanish Breast Cancer Group, Madrid/ES
  • 16 Translational Research, GEICAM (Spanish Breast Cancer Research Group), Madrid/ES
  • 17 GEICAM (Spanish Breast Cancer Research Group), Madrid/ES
  • 18 Serv. Hematologia Y Oncologia Medica, 11Hospital Clínico Universitario de Valencia. INCLIVA Instituto de Investigación Sanitaria- Universitat de València, 46010 - Valencia/ES


Abstract 3679


Incidence of gestational breast cancer (GBC) (during pregnancy, lactation or first year postpartum) ranges from 6-15% of BC in the 20-44 subgroup age. GBC is associated with positive nodes, negative hormonal receptors (HR), triple negative and high grade tumors but little is known at molecular level. We explore specific genomic profiles and clinico-epidemiological features of GBC.


Expression of 105 genes was assessed in 50 evaluable tumors from 70 GBC Spanish patients using nCounter platform. The following signatures were assessed: 1) Intrinsic subtypes; 2) Proliferation (P) and Risk of Recurrence (ROR) scores; 3) Claudin-low and 4) Chemo-Endocrine Sensitivity Predictor (CESP). Genomic profile and clinico-epidemiological data were compared to equivalent nonGBC cohorts from GEICAM/9906 (n = 293) (NCT00129922), Málaga (n = 96) (Cancer Res, 2016 76; P3 07 15) and Alamo III project (n = 1473).


Out of the 70 patients, 43% were diagnosed during pregnancy and 57% postpartum. The table reports patient and tumor characteristics:

n (%) GBC Alamo III 9906 Málaga
Mean age at diagnosis 35 37 37 37
Negative HR 30 (43) 330 (24) 33 (16) 27 (28)
T2-T4 51 (76) 787 (56) 176 (60) 84 (92)
Grade 3 38 (63) 479 (40) 121 (44) 38 (47)
Ki67 (≥20%) 33 (89) 209 (61) 46 (22) 60 (64)
Family history of BC 32 (47) 296 (25) - -
Mean age at first partum 31 26 - -

Intrinsic subtypes in GBC were 44% Basal-like, 22% Her2-enriched, 20% Luminal B and 14% Luminal A; no Claudin-low tumors were identified. Basal-like phenotype was enriched (44% vs 14%, p 


GBC differential biology is suggested by higher Basal-like and lower Luminal A rates, and absence of Claudin-low phenotype, correlating with worse survival and a more aggressive clinico-pathological profile confirmed by a higher ROR-P high rate and lower CESP score.

Legal entity responsible for the study

GEICAM Spanish Breast Cancer Group


Sociedad Española de Oncologia Medica (SEOM): Grant “SEOM Buckler”, Fundacion BBVA: Solidarity project: “BBVA Solidarity Territories“ Donations from two Associations of Breast Cancer Patients “Rosae” and “Santa Agueda”


A. Prat: Consulting Fees (advisory boards) Nanostring Technologies. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings